|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Net sales | |||||
| Cost of sales | |||||
| Gross margin | |||||
| Selling, general, and administrative expense | |||||
| Research and development expense | |||||
| Goodwill impairment | |||||
| Long-lived asset impairment | |||||
| Loss on asset disposal | |||||
| Restructuring expense (Note E) | |||||
| Other — net (Note F) | |||||
| Operating profit | |||||
| Other non-operating (income) expense — net (Note P) | |||||
| Interest expense — net (Note G) | |||||
| Total income (loss) before income taxes | |||||
| Income tax expense (Note H) | |||||
| Net income | |||||
| Basic earnings per share: | |||||
| Net income per share of common stock (in dollars per share) | |||||
| Diluted earnings per share: | |||||
| Net income per share of common stock (in dollars per share) | |||||
| Weighted-average number of shares of common stock outstanding: | |||||
| Basic (in shares) | |||||
| Diluted (in shares) | |||||
Loading...